

Erratum

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg,^{1,5} Paul W. Manley,^{2,5} Werner Breitenstein,² Josef Brügger,² Sandra W. Cowan-Jacob,² Arghya Ray,¹ Brian Huntly,³ Dorian Fabbro,² Gabriele Fendrich,² Elizabeth Hall-Meyers,¹ Andrew L. Kung,^{1,4} Jürgen Mestan,² George Q. Daley,⁴ Linda Callahan,¹ Laurie Catley,¹ Cara Cavazza,¹ Mohammad Azam,⁴ Donna Neuberg,¹ Renee D. Wright,³ D. Gary Gilliland,³ and James D. Griffin^{1,*}

¹Dana-Farber Cancer Institute, Boston, Massachusetts 02115

²Novartis Institutes for Biomedical Research, Basel, CH-4002, Switzerland

³Brigham and Women's Hospital, Boston, Massachusetts 02115

⁴Children's Hospital, Boston, Massachusetts 02115

⁵These authors contributed equally to this work.

*Correspondence: james_griffin@dfci.harvard.edu

In this article (Cancer Cell 7, pp. 129–141), the name of one of the authors was listed incorrectly. The author incorrectly listed as “Azam Mohammed” is actually named Mohammad Azam.